Sales: $1.7 billion
Key Personnel: Pierre-Yves Revol, chairman of Pierre Fabre Foundation and vice chairman Pierre Fabre S.A. Supervisory Board; Eric Ducournau, chief executive officer, dermo-cosmetics division; Michael Danon, senior vice president, legal, pharmaceutical and public affairs; Thierry Denjean, senior vice president, human resources; Luc Péligry, senior vice president, finance and operations; and Marc Alias, director, corporate communications.
Major Products: Skin care and hair care products. Brands include A-Derma, Avène, Ducray, Elancyl, Galénic, Klorane and René Furterer.
New Products: Ictyane moisturizing micellar water, Galenic Agrane Intense Comfort Generous Balm 24 h, Klorane Floral gel eye makeup remover with soothing cornflower.
Comments: Pierre Fabre’s global turnover in 2013 was nearly $3.3 billion, a gain of 1.6%. The company’s dermo-cosmetic business—which covers skin care and hair care brands—had sales of $1.7 billion.
There was sad news last year at this French firm, as founder Pierre Fabre passed in late July 2013.
To ensure the future of the company he founded back in 1961, Fabre had earlier given his shares to the Foundation Pierre Fabre, a recognized public utility. In addition, thanks to an employee shareholding program set up in 2005, 90% of the company’s employees collectively have a 7 % shareholding interest in the company.
Pierre Fabre’s headquarters is located in Castres, but there’s plenty of action in nearby Haute-Garonne. Every year, one million orders are processed and dispatched from Fabre’s Haute-Garonne site, which is celebrating its 40th anniversary this year and covers all dermo-cosmetic and family healthcare products sold worldwide by the group.
Built in 1974, it dispatches more than 25,000 tons of products to group subsidiaries and partners in more than 130 countries, according to the firm.
In 2013, Fabre spent more than $100 million on “investments,” some of which was spent at its dermo-cosmetics manufacturing site in Soual and at a sterile cosmetics production facility in Avene.